Abstract
Eighty patients with prostatic carcinoma were treated by antiandrogen therapy with chlormadinone acetate and diethylstilbestrol diphosphate. Numerous papers have shown that the survival rates of patients with low-grade prostatic carcinomas are higher than those of patients in advanced stages; however, in this study, no statistically significant difference in the ten-year survival rates of these groups was demonstrated. Residual cancer cells in the primary lesions were observed in 90% of the patients who underwent autopsy following death. The results of this study suggest that antiandrogen therapy is not sufficiently effective for the treatment of patients with prostatic carcinoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
